Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

13
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
13
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

6
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
6
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

12
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
12
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

11
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
11
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

12
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
12
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

12
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
12

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Assessment of clinically relevant drugs as feline P-glycoprotein substrates.

Frontiers in veterinary science·2026
Same author

Ilunocitinib-Induced Pancytopenia in an Australian Shepherd Dog with the MDR1 Mutation.

Journal of the American Animal Hospital Association·2026
Same author

Validation of a flow cytometric competitive efflux assay for assessing clinically important drugs as canine P-glycoprotein substrates.

American journal of veterinary research·2026
Same author

Comparison of Human and Canine P-Glycoprotein Substrates at R, P, and H Binding Sites.

Journal of veterinary pharmacology and therapeutics·2025
Same author

Assessment of clinically relevant drugs as feline P-glycoprotein substrates.

Frontiers in veterinary science·2025
Same author

Avermectin-induced neurotoxicity and mortality reported more commonly in cats homozygous for ABCB11930_1931del TC after application of eprinomectin- versus selamectin-containing products.

Journal of the American Veterinary Medical Association·2025

Related Experiment Video

Updated: Feb 16, 2026

The Serial Anesthesia Array for the High-Throughput Investigation of Volatile Agents Using Drosophila melanogaster
06:27

The Serial Anesthesia Array for the High-Throughput Investigation of Volatile Agents Using Drosophila melanogaster

Published on: February 24, 2023

1.1K

Pharmacogenetics.

Katrina L Mealey1

  • 1Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, WA 99164-6610, USA. kmealey@vetmed.wsu.edu

The Veterinary Clinics of North America. Small Animal Practice
|September 21, 2006
PubMed
Summary
This summary is machine-generated.

Pharmacogenetics optimizes drug therapy by studying genetic influences on patient response. This emerging science aims to personalize medicine, improving drug effectiveness and reducing side effects in both humans and animals.

More Related Videos

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
07:35

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

7.5K
The Utility of Stage-specific Mid-to-late Drosophila Follicle Isolation
08:44

The Utility of Stage-specific Mid-to-late Drosophila Follicle Isolation

Published on: December 2, 2013

11.7K

Related Experiment Videos

Last Updated: Feb 16, 2026

The Serial Anesthesia Array for the High-Throughput Investigation of Volatile Agents Using Drosophila melanogaster
06:27

The Serial Anesthesia Array for the High-Throughput Investigation of Volatile Agents Using Drosophila melanogaster

Published on: February 24, 2023

1.1K
Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
07:35

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

7.5K
The Utility of Stage-specific Mid-to-late Drosophila Follicle Isolation
08:44

The Utility of Stage-specific Mid-to-late Drosophila Follicle Isolation

Published on: December 2, 2013

11.7K

Area of Science:

  • Pharmacology
  • Genetics
  • Personalized Medicine

Background:

  • Pharmacogenetics investigates genetic factors influencing drug responses.
  • Current drug prescribing often relies on a one-size-fits-all approach.
  • Optimizing drug efficacy and minimizing toxicity are key clinical challenges.

Purpose of the Study:

  • To highlight the significance of pharmacogenetics in tailoring drug therapy.
  • To underscore the potential of genetic insights for personalized medicine.
  • To review early advancements in the field.

Main Methods:

  • Review of existing literature on pharmacogenetics.
  • Analysis of key discoveries and their clinical implications.
  • Synthesis of findings related to drug response variability.

Main Results:

  • Pharmacogenetics offers a pathway to individualized drug selection and dosage.
  • Early discoveries have already led to improved treatment outcomes.
  • The field is rapidly advancing, promising further therapeutic benefits.

Conclusions:

  • Pharmacogenetics represents a crucial step towards precision medicine.
  • Personalized pharmacotherapy based on genetic profiles can enhance patient care.
  • Continued research in pharmacogenetics is essential for optimizing drug therapy.